A higher incidence of coronary artery disease (CAD) is associated with a lower level of HDL-cholesterol ( 1, 2 ), which is determined by multiple environmental and genetic factors. In the past few years, new therapeutic approaches have focused on fi nding ways to increase HDL ( 3, 4 ). To date, however, only a few environmental interventions, such as diet and exercise, have been successful in raising HDL level ( 5 ), whereas drug therapy development is still ongoing and has targeted only a limited number of proteins such as CETP ( 3, 4 ). In the search for a potential drug target to raise HDL and decrease CAD, the identifi cation of new genes involved in HDL determination is essential.The genetic basis of HDL-cholesterol variation has been widely studied in various animal models. In humans, recent genome-wide association studies (GWAS) have identifi ed known HDL genes such as LIPG and CETP in addition to new genes such as GALNT2 ( 6 ). These known genes, however, explain only a small proportion of the total variation, indicating that additional genes are yet to be discovered. Mouse models are a powerful strategy for identifying such genes. A large overlap exists among species for quantitative trait loci (QTL) and genes involved in lipid metabolism ( 7 ). Many study methodologies are similar between human and mouse, but mouse studies offer advantages by capitalizing on genomics tools that are not available and practical for studies of human populations. To date, our laboratory and those of others have identifi ed over 35 mouse HDL QTL (as reviewed in Wang et al., Refs. 7,8 ). In addition, we and others have developed bioinformatics tools to narrow the QTL interval to just a few candidate genes ( 9, 10 ). Application of these tools has led to the discovery of single genes underlying QTL for HDL and